Tuesday, 02 January 2024 12:17 GMT

Equillium To Participate In Stifel's 2026 Virtual Immunology And Inflammation Forum


(MENAFN- GlobeNewsWire - Nasdaq) LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel's 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT.

Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.

A live webcast of the fireside chat may also be accessed on the Events & Presentations page, located under the Investor Relations section on equilliumbio.com. A replay of the webcast will be available for approximately 45 days following the conference.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.

For more information, visit .

Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
...


MENAFN16092026004107003653ID1111673776



GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story